BC Week In Review | Dec 23, 2013
Clinical News

TxBCardio immunoturbidimetric regulatory update

Corgenix and partner Randox announced the submission of a 510(k) application to FDA for the TxBCardio immunoturbidimetric (IT) assay for use with automated chemistry analyzers to determine aspirin effect in apparently healthy individuals. Corgenix developed...
BC Week In Review | Jan 17, 2011
Company News

Corgenix Medical Corp. sales and marketing update

Corgenix's AspirinWorks Test received a 28% reimbursement increase from CMS to $30.92 in 2011 from $25.95 in 2010. Corgenix markets the ELISA test to determine levels of 11-dehydro thromboxane B2 in urine to determine aspirin...
BC Week In Review | Oct 27, 2008
Clinical News

AspirinWorks: Additional Phase III data

A subgroup analysis of 3,261 aspirin-treated patients in the double-blind, placebo-controlled, international Phase III CHARISMA trial showed that patients with the highest quartile concentration of urine 11-dehydro thromboxane B2 had a 66% increased risk for...
BC Week In Review | Apr 7, 2008
Company News

Corgenix Medical Corp., Randox Laboratories deal

Corgenix and Randox will adapt Corgenix's AspirinWorks test for use with automated chemistry analyzers. Randox will manufacture the test, and the companies will share global distribution rights. The test is approved in the U.S. and...
BC Week In Review | Feb 4, 2008
Company News

Corgenix Medical Corp., Quest Diagnostics sales and marketing update

Quest will offer Corgenix' AspirinWorks test to physicians and laboratories. The test determines the effectiveness of aspirin therapy in reducing the risk of heart attack and stroke. Corgenix acquired rights to the ELISA test kit,...
BC Week In Review | Jun 11, 2007
Clinical News

AspirinWorks regulatory update

FDA granted 510(k) clearance for the AspirinWorks test to help determine the effectiveness of aspirin therapy in reducing the risk of heart attack and stroke. CONX acquired rights to the ELISA test kit, which is...
BC Week In Review | Mar 12, 2007
Company News

Corgenix Medical Corp., Creative Clinical Concepts Inc. deal

CONX acquired rights to Creative Clinical Concept's AspirinWorks business for an undisclosed sum. Creative Clinical Concepts is now eligible for milestones and royalties. Under a 2004 deal, the companies had agreed to shared expenses and...
BC Week In Review | Jul 24, 2006
Clinical News

AspirinWorks regulatory update

CONX submitted a 510(k) application to the FDA for AspirinWorks, an ELISA test determines levels of 11-dehydro thromboxane B2 in urine. The kit is used to measure an individual's response to doses of aspirin Corgenix...
Items per page:
1 - 8 of 8